Baroda BNP Paribas Health and Wellness Fund
- NAV as on 9 Nov 2026
- ₹11.11+2.72%1 day
- Return since launch
- 5.9%
- 52-week range
- ₹8.96 — ₹10.91
- AUM
- ₹487 Cr
Baroda BNP Paribas Health and Wellness Fund is a Sectoral-Pharma equity fund from Baroda BNP Paribas Mutual Fund with ₹487 Cr under management, launched in 2025. The expense ratio is 2.70% and the SEBI riskometer reading is Very High.
Performance
Baroda BNP Paribas Health and Wellness Fund NAV and returns
Growth of the fund against its category average over the period you pick.
Over 1Y this fund returned +15.7% against +19.9% for its category.
Performance
Returns
How the fund has done against its category and its benchmark.
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1Y | 24.3% | +3.5 pts | 20.8% | 29.1% |
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1M | 8.3% | −0.1 pts | 8.4% | 8.5% |
| 3M | 3.4% | −0.3 pts | 3.7% | 3.7% |
| 6M | 11.7% | −2.3 pts | 14.0% | 13.6% |
| 1Y | 15.8% | −5.0 pts | 20.8% | 19.4% |
Since launch (9 Jun 2025): 5.9%
Returns over one year are annualised. Shorter periods are absolute.
Costs & terms
Costs and terms
What the fund charges each year, and the rules around putting money in and taking it out.
Costs
2.70%
Expense ratio as on 6 Nov 2026
Charged yearly and already deducted from the NAV.
- Base expense
- 2.10%
- Brokerage
- 0.08%
- Transaction charges
- 0.00%
- Statutory levies
- 0.52%
- Exit load
- Exit Load for units in excess of 10% of the investment,1% will be charged for redemption within 1 year.
- Lock-in
- None
Terms
- Min SIP
- ₹3,000
- Min lumpsum
- ₹5,000
- Plan
- GROWTH
- Fund type
- OPEN-ENDED
- Benchmark
- BSE Healthcare TRI
- Short-term capital gains
- Returns taxed at 20% if you redeem before 1 year
- Long-term capital gains
- After 1 year, returns above ₹1.25 lakh in a financial year are taxed at 12.5%
Risk
Risk
What the riskometer means for this fund, and how its ratios sit against the category.
Your principal is treated as being at very high risk — typically small cap, sectoral and thematic equity schemes.
Portfolio
Baroda BNP Paribas Health and Wellness Fund portfolio
Portfolio as of 30 Sep 2026
Asset allocation
- Equity97.1%
- Debt2.8%
- Other0.2%
Market cap split
- Large32.1%
- Mid47.7%
- Small20.2%
- P/E
- 44.64
- P/B
- 6.93
Top holdings
| Holding | Sector | Weight | Value | 3M chg | 6M chg | 1Y chg |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 8.58% | ₹41.83 Cr | +7.58% | +10.23% | +10.64% |
| Torrent Pharmaceuticals Ltd. | Healthcare | 7.88% | ₹38.40 Cr | +5.43% | +5.32% | +3.81% |
| Divi's Laboratories Ltd. | Healthcare | 7.82% | ₹38.10 Cr | +5.35% | +1.95% | +7.64% |
| Ipca Laboratories Ltd. | Healthcare | 6.13% | ₹29.87 Cr | +5.80% | +5.28% | +2.82% |
| Laurus Labs Ltd. | Healthcare | 6.09% | ₹29.70 Cr | +6.31% | +4.43% | — |
| Lupin Ltd. | Healthcare | 5.79% | ₹28.22 Cr | +6.56% | +6.29% | +1.87% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 5.28% | ₹25.72 Cr | +4.87% | +3.24% | +6.03% |
| Fortis Healthcare Ltd. | Healthcare | 3.98% | ₹19.40 Cr | +4.32% | +3.09% | +1.58% |
| Dr. Lal Pathlabs Ltd. | Healthcare | 3.47% | ₹16.89 Cr | +2.53% | +2.55% | +1.01% |
| Mankind Pharma Ltd. | Healthcare | 3.34% | ₹16.27 Cr | +2.99% | +1.17% | +7.53% |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 3.11% | ₹15.18 Cr | +3.19% | +1.24% | — |
| Aurobindo Pharma Ltd. | Healthcare | 3.09% | ₹15.05 Cr | +2.85% | +2.53% | — |
| Others | Others | 2.94% | ₹14.22 Cr | +5.10% | +9.04% | +15.76% |
| Astrazeneca Pharma India Ltd. | Healthcare | 2.79% | ₹13.61 Cr | +3.87% | +3.92% | +3.33% |
| Abbott India Ltd. | Healthcare | 2.50% | ₹12.21 Cr | +2.07% | +5.53% | +4.29% |
| Emcure Pharmaceuticals Ltd. | Healthcare | 2.39% | ₹11.66 Cr | +3.60% | +3.36% | — |
| Acutaas Chemicals Ltd. | Healthcare | 2.36% | ₹11.48 Cr | +2.30% | +1.74% | — |
| Zydus Lifesciences Ltd. | Healthcare | 2.24% | ₹10.92 Cr | +2.51% | — | — |
| Max Financial Services Ltd. | Financial | 2.21% | ₹10.78 Cr | +2.25% | — | — |
| Aster DM Quality Care Ltd. | Healthcare | 2.15% | ₹10.46 Cr | +2.41% | +3.25% | +4.08% |
| Concord Biotech Ltd. | Healthcare | 2.11% | ₹10.30 Cr | +1.74% | — | +1.34% |
| Ajanta Pharma Ltd. | Healthcare | 1.56% | ₹7.60 Cr | +1.95% | +1.91% | +2.91% |
| Symbiotec Pharmalab Ltd. | Healthcare | 1.47% | ₹7.15 Cr | — | — | — |
| Nephrocare Health Services Ltd. | Healthcare | 1.42% | ₹6.93 Cr | +1.84% | +1.48% | — |
| Metropolis Healthcare Ltd. | Healthcare | 1.33% | ₹6.50 Cr | +1.27% | +1.05% | — |
| Dr. Reddy's Laboratories Ltd. | Healthcare | 1.26% | ₹6.17 Cr | +1.23% | +1.58% | +1.99% |
| Manipal Health Enterprises Ltd. | Healthcare | 1.23% | ₹6.00 Cr | — | — | — |
| Gland Pharma Ltd. | Healthcare | 1.19% | ₹5.80 Cr | +1.13% | +2.96% | +2.92% |
| Cipla Ltd. | Healthcare | 1.10% | ₹5.38 Cr | +1.06% | +1.07% | +5.44% |
| Narayana Hrudayalaya Ltd. | Healthcare | 0.97% | ₹4.75 Cr | — | — | — |
| Inventurus Knowledge Solutions Ltd. | Services | 0.90% | ₹4.37 Cr | +1.52% | +1.29% | — |
| Glaxosmithkline Pharmaceuticals Ltd. | Healthcare | 0.68% | ₹3.32 Cr | — | — | — |
| Life Insurance Corporation of India | Insurance | 0.47% | ₹2.28 Cr | — | — | — |
| Procter & Gamble Health Ltd. | Healthcare | 0.17% | ₹0.85 Cr | +0.57% | — | — |
Sectors
Instruments
Recent changes
| Holding | From | To | Weight |
|---|---|---|---|
| Others | 1.02% | 2.78% | +1.76% |
| Narayana Hrudayalaya Ltd. | 0.00% | 0.97% | +0.97% |
| Medplus Health Services Ltd. | 0.93% | 0.00% | -0.93% |
| Astrazeneca Pharma India Ltd. | 3.56% | 2.79% | -0.77% |
| Fortis Healthcare Ltd. | 4.50% | 3.98% | -0.52% |
| Laurus Labs Ltd. | 5.66% | 6.09% | +0.43% |
| Sun Pharmaceutical Industries Ltd. | 9.01% | 8.58% | -0.43% |
| Procter & Gamble Health Ltd. | 0.57% | 0.17% | -0.40% |
| Glenmark Pharmaceuticals Ltd. | 3.42% | 3.11% | -0.31% |
| Symbiotec Pharmalab Ltd. | 1.18% | 1.47% | +0.29% |
| Mankind Pharma Ltd. | 3.10% | 3.34% | +0.24% |
| Dr. Lal Pathlabs Ltd. | 3.24% | 3.47% | +0.23% |
| Max Financial Services Ltd. | 2.43% | 2.21% | -0.22% |
| Abbott India Ltd. | 2.29% | 2.50% | +0.21% |
| Lupin Ltd. | 5.99% | 5.79% | -0.20% |
| Divi's Laboratories Ltd. | 8.01% | 7.82% | -0.19% |
| Apollo Hospitals Enterprise Ltd. | 5.44% | 5.28% | -0.16% |
| Metropolis Healthcare Ltd. | 1.49% | 1.33% | -0.16% |
| Dr. Reddy's Laboratories Ltd. | 1.14% | 1.26% | +0.12% |
| Acutaas Chemicals Ltd. | 2.24% | 2.36% | +0.12% |
| Torrent Pharmaceuticals Ltd. | 7.99% | 7.88% | -0.11% |
| Ipca Laboratories Ltd. | 6.23% | 6.13% | -0.10% |
| Zydus Lifesciences Ltd. | 2.15% | 2.24% | +0.09% |
| Aster DM Quality Care Ltd. | 2.23% | 2.15% | -0.08% |
| Ajanta Pharma Ltd. | 1.49% | 1.56% | +0.07% |
| Nephrocare Health Services Ltd. | 1.35% | 1.42% | +0.07% |
| Gland Pharma Ltd. | 1.14% | 1.19% | +0.05% |
| Inventurus Knowledge Solutions Ltd. | 0.85% | 0.90% | +0.05% |
| Aurobindo Pharma Ltd. | 3.05% | 3.09% | +0.04% |
| Manipal Health Enterprises Ltd. | 1.27% | 1.23% | -0.04% |
| Glaxosmithkline Pharmaceuticals Ltd. | 0.72% | 0.68% | -0.04% |
| Concord Biotech Ltd. | 2.14% | 2.11% | -0.03% |
| Emcure Pharmaceuticals Ltd. | 2.38% | 2.39% | +0.01% |
| Cipla Ltd. | 1.11% | 1.10% | -0.01% |
| Life Insurance Corporation of India | 0.48% | 0.47% | -0.01% |
Compare
Similar funds
The rest of the category, so this fund’s numbers have something to sit against.
| Fund | AUM | Expense | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| Category average | ₹2,934 Cr | 1.89% | 36.5% | 20.8% | 21.6% |
 SBI Healthcare Opportunities Fund | ₹6,067 Cr | 1.98% | 35.0% | 19.9% | 22.6% |
 HDFC Pharma And Healthcare Fund | ₹3,501 Cr | 2.11% | 39.6% | 25.8% | — |
 Mirae Asset Healthcare Fund | ₹3,494 Cr | 2.01% | 37.3% | 20.2% | 21.1% |
 UTI Healthcare Fund | ₹1,430 Cr | 2.21% | 30.6% | 18.4% | 21.1% |
 ICICI Prudential Nifty Pharma Index Fund | ₹177 Cr | 1.13% | 39.9% | 19.9% | — |
About
About this fund
The scheme’s own words, its benchmark and the people running it.
Investment objective
The scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns.
Fund managers
- Ankeet PandyaMBA FinancePrior to joining Baroda BNP Paribas Mutual Fund, he was working with InCred Asset management Private Ltd, Motilal Oswal Securities Ltd and Elara Capital India Private Ltd.
- Rohan KordeMr. Korde is a Masters in Management Studies (Finance), Bachelor of CommercePrior to joining Baroda BNP Paribas Mutual Fund, he has worked with ITI Mutual Fund, BOB Capital Markets as Vice President
Tools
Return calculator
What ₹10,000 a month in this fund would have grown to over each period, based on its past returns.
| Over the past | Total investment | Would’ve become | Growth | Returns |
|---|---|---|---|---|
| 6 months11.72% absolute | ₹60,000 | ₹67,032 | 11.72% | |
| 1 year15.80% annualised | ₹1,20,000 | ₹1,30,783 | 8.99% |
Returns for 1 year and longer are annualised (CAGR); 6-month figures are absolute. Past returns are not a forecast.
How this is calculated
Each monthly instalment grows at the fund’s annualised return ÷ 12 per month until the end of the period, the same formula as our SIP calculator.
The amount compounds once a year at the fund’s CAGR for that period, the same formula as our lumpsum calculator.
Questions
Frequently asked questions
The things people ask about this scheme.